Company Overview
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.29.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +52.72% |
| 6 Months: | +27.51% |
| 3 Months: | +15.37% |
| 1 Month: | +10.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PYPD PolyPid Ltd. PHARMA | 5.33 | -4.07 | $108.26M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 7.58M | 9.40M | 7.46M | 8.53M | 7.76M |
| Operating Income | - | -7.58M | -9.40M | -7.46M | -8.53M | -7.76M |
| EBITDA | - | -7.58M | -9.40M | -7.46M | -8.85M | -7.76M |
| Interest Expense | 286.00K | 678.00K | 521.00K | - | - | - |
| Pretax Income | - | -8.26M | -9.92M | -7.43M | -8.55M | -7.73M |
| Tax Provision | - | 11.00K | 53.00K | 22.00K | -81.00K | 0 |
| Net Income | - | -8.27M | -9.98M | -7.45M | -8.47M | -7.73M |
| Diluted EPS | - | -0.70 | -0.78 | -0.37 | -0.41 | -0.35 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 38.89M | 22.87M | 28.03M | 32.97M |
| Operating Income | - | -38.89M | -22.87M | -28.03M | -32.97M |
| EBITDA | - | -37.17M | -20.36M | -25.85M | -31.83M |
| Interest Expense | - | 540.00K | 1.62M | 1.51M | 874.00K |
| Pretax Income | - | -39.43M | -23.80M | -28.98M | -34.16M |
| Tax Provision | - | 129.00K | 69.00K | 42.00K | 5.00K |
| Net Income | - | -39.56M | -23.86M | -29.02M | -34.17M |
| Diluted EPS | - | -60.90 | -16.99 | -4.91 | -2.09 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 25.97M | 15.37M | 25.22M | 22.31M |
| Current Assets | - | 14.19M | 6.07M | 16.57M | 15.23M |
| Cash & Equivalents | - | 8.55M | 5.31M | 15.64M | 6.40M |
| Inventory | - | - | - | 0 | 1.11M |
| Receivables | 118.00K | 298.00K | - | - | - |
| Total Liabilities | - | 20.14M | 17.47M | 17.54M | 11.33M |
| Current Liabilities | - | 8.55M | 7.29M | 12.68M | 7.74M |
| Long Term Debt | - | 7.57M | 6.38M | 634.00K | - |
| Total Debt | - | 13.73M | 11.78M | 9.62M | 2.80M |
| Total Equity | - | 5.83M | -2.10M | 7.68M | 10.97M |
| Shares Outstanding | - | 661.73K | 1.65M | 10.19M | 18.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.32M | -17.24M | -21.96M | -27.88M |
| Investing Cash Flow | - | 16.57M | 3.80M | -330.00K | -6.70M |
| Financing Cash Flow | - | 16.43M | 9.98M | 32.42M | 25.37M |
| Capital Expenditure | - | -1.77M | -196.00K | -76.00K | -210.00K |
| Free Cash Flow | - | -36.08M | -17.43M | -22.04M | -28.09M |
| Net Change in Cash | - | -1.31M | -3.46M | 10.12M | -9.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -678.6% | 1,138.6% | -377.7% | -311.4% |
| ROCE % | - | -223.3% | -282.8% | -223.5% | -226.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 7.89% | 1.50M | $7.84M |
| 2 | Rosalind Advisors, Inc. | 2.04% | 389.45K | $2.03M |
| 3 | DAFNA Capital Management, LLC | 1.09% | 207.90K | $1.08M |
| 4 | Morgan Stanley | 0.65% | 123.14K | $641.54K |
| 5 | Renaissance Technologies, LLC | 0.61% | 116.62K | $607.58K |
| 6 | Marshall Wace LLP | 0.60% | 115.01K | $599.22K |
| 7 | Adar1 Capital Management, LLC | 0.54% | 103.95K | $541.58K |
| 8 | Symmetry Peak Management LLC | 0.53% | 100.88K | $525.59K |
| 9 | J. Goldman & Co., L.P. | 0.52% | 99.18K | $516.74K |
| 10 | Jane Street Group, LLC | 0.44% | 83.13K | $433.09K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PYPD
How (PYPD) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNaTktQWtPX1hrQlJaX1lSYXdDYzZZaThjUERjUllaZ0Q0d3V0alVzc0NwVWhFZnk2eUw1WF9OTE5HR2FpLVpCTlFKNktGb2pzLVg2OTNDQ2FhVHhRVHFWRjhvV0piQml0Zm9xN3JycFdoTzJTYktORng4eWhaY0FHS3V2bkQ1aUxwRGZlbG…
PYPD - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1vamdYVkxCdXNEaDMtU0phTzZOSEpSNlZuUUNPQUNhQkJ5RHR5NHhOeHlpOEpub2tjV0luUVF4RW56SG56SWc?oc=5" target="_blank">PYPD</a> <font color="#6f6f6f">Finviz</font>…
PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQcjFsX3VHZU80MlhLb2xiZEZYODhlc0hmZmtRRFd0U2FXZFR2X09wR2NfWXlMWUdTRUxmYnRKNEh2Y3B6NThWZjAxOVZzcElTcFZ3NldIT0hXRUxrZ0NDajNScXJUcFRYMnd6Y0VpZGROd1NtZk4xN0FwbVlOVFQ4cC1TRktzWENybXpobT…
PYPD Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9UUjhGRFQwTl9Ba2xPTXdTZm11UktScXdLbzhTVEFwd1ZnUk1KN0VaNzZ3eE1jZktCSHlfTWk5ejJGRG9XalJjaENLRmtJcEtPaEtRR19YRDQ4WnZaSl82MTJfRS1IZlh1X0otYmpHNldyLWtoQmJDOVFn?oc=5" target="_blank">PYP…
$PYPD ($PYPD) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNUUNWa1F6dVptWnFreXR4OTFmNG1OdmlGMGI0UENZSHdmVmVkT2kyS25ManRySlA4WktZX2ZIbU5yQjV3M2pjSXNDMEM4US1IQUcxR3hLM3AtN3NNTllZWEVOWVBFU1ZCZ3FjZ0VqZDN3QTQzWVowYmtaNFoyel94cEN4N25OTmc?oc=5" …
PolyPid (PYPD): Will The November FDA Decision Propel The Stock? - RTTNews
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOTGdZRTVzWTdUcHdqRm9QMTFtS1dpSkZQcHVJRjZQeEdKT2NsLVBnNHNFZ3hGc2xHczNlQzd0WE5jZl9OY1p0QjQtWW4takFGVndycHQxS3ZuUEFYejF4Tl9rSVItLURzaDhZNXg4UWpZa0wzZnotWHl2YU5BU3B5bGFFT2RGcDhqR3hoQV…
PYPD — Frequently Asked Questions
What is the current share price of PolyPid Ltd. (PYPD)?
As of 2026-09-19 21:16 PDT, PolyPid Ltd. (PYPD) trades at $5.33 on NasdaqCM. Its 52-week range is $3.15 to $5.58.
What is the market capitalisation of PYPD?
PolyPid Ltd. (PYPD) has a market capitalisation of $108.26M on NasdaqCM.
What is the P/E ratio of PYPD?
PYPD trades at a trailing price-to-earnings (P/E) ratio of -4.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 19.66.
Is PYPD a good stock to buy?
This page provides a data-driven analysis of PolyPid Ltd. (PYPD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.